Yinhua CSI Innovative Drugs Industry ETF (159992) falls 1.92%, with a net inflow of 269 million yuan over the past 5 trading days

NewTimeSpace (newtimespace.com) News, as of 14:10 on May 25, 2026, Yinhua Innovative Drug ETF (159992) fell 1.92%, with the latest price at 0.77 yuan. (The stocks listed above are only index constituents and do not constitute any specific recommendation.)

In terms of liquidity, Yinhua Innovative Drug ETF recorded an intraday turnover rate of 3.69% and a trading volume of 543 million yuan. Over a longer time frame, as of May 22, the ETF's average daily trading volume over the past month reached 688 million yuan, ranking first among comparable funds.

In terms of scale, Yinhua Innovative Drug ETF saw a significant increase of 173 million yuan in scale over the past week, with the new scale increase ranking 1/7 among comparable funds. (Data source: Wind)

In terms of shares, the latest share count of Yinhua Innovative Drug ETF reached 19.158 billion units, hitting a one-year high and ranking 1/7 among comparable funds. (Data source: Wind)

In terms of capital flows, the latest net inflow for Yinhua Innovative Drug ETF was 150 million yuan. Over a longer time frame, within the past five trading days, there were three days of net inflow, attracting a total of 269 million yuan, with an average daily net inflow of 53.8382 million yuan. (Data source: Wind)

Data shows that leveraged funds are continuously positioning. Yinhua Innovative Drug ETF recorded a net margin financing purchase of 4.1549 million yuan month-to-date, with the latest margin financing balance standing at 636 million yuan. (Data source: Wind)

As of May 22, the net value of Yinhua Innovative Drug ETF rose by 13.34% over the past two years. From the perspective of return capability, as of May 22, 2026, since its inception, the ETF achieved a highest single-month return of 22.79%, a longest streak of consecutive up months of 4 months, a maximum cumulative gain during that streak of 53.27%, and an average return of 6.47% in up months. As of May 22, 2026, the ETF's annualized excess return over its benchmark for the past two years was 0.64%.

In terms of drawdown, as of May 22, 2026, Yinhua Innovative Drug ETF recorded a drawdown of 0.18% relative to its benchmark since the beginning of the year.

In terms of fees, Yinhua Innovative Drug ETF has a management fee rate of 0.50% and a custodian fee rate of 0.05%.

In terms of tracking accuracy, as of May 22, 2026, the one-month tracking error of Yinhua Innovative Drug ETF was 0.014%, achieving relatively high tracking accuracy among comparable funds.

From a valuation perspective, the latest price-to-earnings (PE-TTM) ratio of the CSI Innovative Drug Industry Index, which Yinhua Innovative Drug ETF tracks, is only 45.14 times, standing at the 11.07% percentile over the past year. This means the valuation is lower than over 88.93% of the time in the past year, placing it at a historical low.

Yinhua Innovative Drug ETF closely tracks the CSI Innovative Drug Industry Index. The CSI Innovative Drug Industry Index selects no more than 50 of the most representative listed company securities whose main businesses involve innovative drug research and development as index constituents, in order to reflect the overall performance of the securities of listed companies in the innovative drug industry.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.